Enhancing Utility of Neuropsychological Evaluation for Earlier and Effective Diagnosis of Dementia in Parkinson's Disease

NCT ID: NCT07114354

Last Updated: 2025-08-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

275 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-18

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dementia is observed in 80% of people living with advanced stage Parkinson's disease, however, there are inadequate opportunities for early and effective diagnosis of dementia in current clinical practice. This study aims to identify whether a new tool called PDCogniCare, can improve detection of dementia in people living with Parkinson's disease, and to explore what factors might influence its use in healthcare services.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The PDCogniCare tool integrates best practice guidelines for cognitive evaluations in people living with Parkinson's disease, along with a tailored digital platform to support guideline implementation and routinely track cognitive changes throughout the disease course. We hypothesize that PDCogniCare will significantly enhance cognitive evaluations within healthcare services. Embedded process and economics evaluations will inform implementation and sustainable business models of PDCogniCare.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dementia (Diagnosis) Parkinson Disease Dementia (PDD) Parkinson Disease (PD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PDCogniCare

All eligible people living with Parkinson's disease who consent to participate will be registered into the PDCogniCare platform.

Group Type OTHER

PDCogniCare platform

Intervention Type OTHER

Digital platform designed to support early and accurate detection of dementia in people living with Parkinson's disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PDCogniCare platform

Digital platform designed to support early and accurate detection of dementia in people living with Parkinson's disease

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* People living with idiopathic Parkinson's disease, one year or more post-diagnosis, attending Movement Disorder Clinics

Exclusion Criteria

* People with severe Parkinson's disease who aren't able to communicate
* People with comorbid neurological conditions (e.g. Stroke)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical Research Future Fund

OTHER

Sponsor Role collaborator

Metro South Health

OTHER

Sponsor Role collaborator

Metro North Health

UNKNOWN

Sponsor Role collaborator

Queensland University of Technology

OTHER

Sponsor Role collaborator

University of Sydney

OTHER

Sponsor Role collaborator

OPN365

UNKNOWN

Sponsor Role collaborator

Australian Dementia Network

UNKNOWN

Sponsor Role collaborator

Dementia Australia

UNKNOWN

Sponsor Role collaborator

Lions Club of Brisbane Inner North

UNKNOWN

Sponsor Role collaborator

Parkinson's Queensland

UNKNOWN

Sponsor Role collaborator

The University of Queensland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nadeeka Dissanayaka

Role: CONTACT

+617 3346 5577

Tiffany Au

Role: CONTACT

References

Explore related publications, articles, or registry entries linked to this study.

Pourzinal D, King J, Sivakumaran K, Yang J, McCann E, Mitchell LK, Brooks D, Lehn A, Liddle J, Pachana NA, Tinson H, Shrubsole K, Bailey DX, Dissanayaka NN. Evaluating evidence for a neuropsychological toolkit to predict cognitive decline in PD: A systematic review. Clin Neuropsychol. 2025 Jun 4:1-28. doi: 10.1080/13854046.2025.2511966. Online ahead of print.

Reference Type BACKGROUND
PMID: 40464273 (View on PubMed)

Pourzinal D, Elgey C, Bailey DX, Yang J, Lehn A, Tinson H, Liddle J, Brooks D, Naismith SL, Shrubsole K, Marsh R, Mitchell LK, Pachana NA, King J, Dissanayaka NN. Diagnosis, evaluation & management of cognitive disorders in Parkinson's disease: A systematic review. Int Psychogeriatr. 2025 May 12:100081. doi: 10.1016/j.inpsyc.2025.100081. Online ahead of print.

Reference Type BACKGROUND
PMID: 40360335 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HREC/2023/MNHA/100098

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.